Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia

Journal of the American Society of Nephrology

Volumn 27, Issue 3, 2016, Pages 903-913

  Thadhani, Ravi ^a   Hagmann, Henning ^b   Schaarschmidt, Wiebke ^c   Roth, Bernhard ^c   Cingoez, Tuelay ^b   Karumanchi, S Ananth ^d,e   Wenger, Julia ^a   Lucchesi, Kathryn J ^a   Tamez, Hector ^c   Lindner, Tom ^f   Fridman, Alexander ^g   Thome, Ulrich ^c   Kribs, Angela ^c   Danner, Marco ^c   Hamacher, Stefanie ^c   Mallmann, Peter ^g,h   Stepan, Holger ^b   Benzing, Thomas ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Renal Division and Department of Medicine and Center for Molecular Medicine   (United States)

^c Department of Neonatology ^*  (United States)

^d Informatics and Epidemiology   (United States)

^e UNIVERSITY OF COLOGNE   (Germany)

^f Division of Nephrology   (United States)

^g UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^h HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DEXTRAN SULFATE; PLACENTAL GROWTH FACTOR; PROTEIN; PROTEIN TYROSINE KINASE; SODIUM CHLORIDE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; FLT1 PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 1;

ADULT; ANTIHYPERTENSIVE THERAPY; APGAR SCORE; APHERESIS; ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FETUS HEART RATE; FETUS WEIGHT; GESTATIONAL AGE; HEMATOCRIT; HUMAN; LENGTH OF STAY; NEWBORN INTENSIVE CARE; PILOT STUDY; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; ADVERSE EFFECTS; BLOOD; BLOOD PRESSURE; CHEMISTRY; NEWBORN; OXYGEN THERAPY; PRE-ECLAMPSIA; PREGNANCY; PREMATURE BIRTH; PROCEDURES; YOUNG ADULT;

ADULT; BIRTH WEIGHT; BLOOD COMPONENT REMOVAL; BLOOD PRESSURE; DEXTRAN SULFATE; FEMALE; GESTATIONAL AGE; HEART RATE, FETAL; HUMANS; INFANT, NEWBORN; OXYGEN INHALATION THERAPY; PILOT PROJECTS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY MAINTENANCE; PREMATURE BIRTH; PROTEINURIA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84959915368     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015020157     Document Type: Article

References (44)

1. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ: Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 156: 918-930, 2008
2. Sibai BM: Prevention of preeclampsia: a big disappointment. Am J Obstet Gynecol 179: 1275-1278, 1998
3. Walker JJ: Pre-eclampsia. Lancet 356: 1260-1265, 2000
4. Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, Shackelford KA, Steiner C, Heuton KR, Gonzalez-Medina D, Barber R, Huynh C, Dicker D, et al. : Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for theGlobal Burden of Disease Study 2013. Lancet 384: 980-1004, 2014
5. Levine RJ,Maynard SE,Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl JMed 350: 672-683, 2004
6. McCoy S, Baldwin K: Pharmacotherapeutic options for the treatment of preeclampsia. Am J Health Syst Pharm 66: 337-344, 2009
7. Maynard SE, Min JY, Merchan J, Lim KH, Li J,Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658, 2003
8. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA: Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125: 911-919, 2012
9. Thadhani R: Inching towards a targeted therapy for preeclampsia. Hypertension 55: 238-240, 2010
10. Gilbert JS, Verzwyvelt J, Colson D, Arany M, Karumanchi SA, Granger JP: Recombinant vascular endothelial growth factor121 infusion lowersblood pressure and improves renal function in rats with placentalischemiainduced hypertension. Hypertension 55: 380-385, 2010
11. Siddiqui AH, Irani RA, Zhang Y, Dai Y, Blackwell SC, Ramin SM, Kellems RE, Xia Y: Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice. Am J Hypertens 24: 606-612, 2011
12. BergmannA,Ahmad S,CudmoreM,GruberAD, Wittschen P, Lindenmaier W, Christofori G, Gross V, Gonzalves AC, Gröne HJ, Ahmed A,Weich HA: Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell MolMed 14[6B]: 1857-1867, 2010
13. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, Hemphill L, Rigby AC, Khedkar S, Lindner TH,Mallmann P, Stepan H, Karumanchi SA, Benzing T: Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124: 940-950, 2011
14. Teruel JL, Lasunción MA, Navarro JF, Carrero P, Ortuño J: Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption. Metabolism 44: 929-933, 1995
15. Kroon AA, Swinkels DW, van Dongen PW, Stalenhoef AF: Pregnancy in a patient with homozygous familial hypercholesterolemia treated with longterm low-density lipoprotein apheresis. Metabolism 43: 1164-1170, 1994
16. Klingel R, Göhlen B, Schwarting A, Himmelsbach F, Straube R: Differential indication of lipoprotein apheresis during pregnancy. Ther Apher Dial 7: 359-364, 2003
17. Fan X, Rai A, Kambham N, Sung JF, Singh N, Petitt M, Dhal S, Agrawal R, Sutton RE, Druzin ML, Gambhir SS, Ambati BK, Cross JC, Nayak NR: Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. J Clin Invest 124: 4941-4952, 2014
18. World Health Organization: Preterm Birth. Fact Sheet No. 363. 2014 (November). http://www. who. int/mediacentre/factsheets/fs363/en/ Accessed April, 2015
19. SibaiBM,Mercer BM, Schiff E, Friedman SA: Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 171: 818-822, 1994
20. Ward RM: Maternal-placental-fetal unit: unique problems of pharmacologic study. Pediatr Clin North Am 36: 1075-1088, 1989
21. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA, Thadhani R, Wolf M, Harger G, Markovic N: Extraplacental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 26: 563-573, 2005
22. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA: First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 89: 770-775, 2004
23. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I,Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H: An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 202: 161. e1-161. e111, 2010
24. Winkler K, HoffmannMM, PutzG. Letter byWinkler et al regarDing article, Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 125: e522; author reply e523-524, 2012
25. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278: 12605-12608, 2003
26. Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O'Young G, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Protter AA, Pollitt NS: Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50: 686-692, 2007
27. Wagner SJ, Craici IM, Grande JP, Garovic VD: From placenta to podocyte: vascular and podocyte pathophysiology in preeclampsia. Clin Nephrol 78: 241-249, 2012
28. Smithies O: Why the kidney glomerulus does not clog: a gel permeation/ diffusion hypothesis of renal function. Proc Natl Acad Sci U S A 100: 4108-4113, 2003
29. Berks D, Steegers EA,Molas M, Visser W: Resolution of hypertension and proteinuria after preeclampsia. Obstet Gynecol 114: 1307-1314, 2009
30. Hovland A,Hardersen R, Sexton J,Mollnes TE, Lappegård KT:Different inflammatory responses induced by three LDL-lowering apheresis columns. J Clin Apher 24: 247-253, 2009
31. Gillon TE, Pels A, von Dadelszen P, MacDonell K, Magee LA: Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS ONE 9: e113715, 2014
32. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ: Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev (1): CD002252, 2007
33. Podymow T, August P: Antihypertensive drugs in pregnancy. Semin Nephrol 31: 70-85, 2011
34. Townsley DM: Hematologic complications of pregnancy. Semin Hematol 50: 222-231, 2013
35. Sunderji S, Gaziano E, Wothe D, Romero R, Kusanovic JP, Rogers L, Hodges-Savola C, Roberts S,Wassenberg J: Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 202: 40. e41-40. e47, 2010.
36. Schaarschmidt W, Rana S, Stepan H: The course of angiogenic factors in early-vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med 41: 511-516, 2013
37. Ohkuchi A, Hirashima C, Matsubara S, Takahashi K, Matsuda Y, Suzuki M: Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia. Hypertension 58: 859-866, 2011
38. Wu FT, Stefanini MO, Mac Gabhann F, Popel AS: A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS ONE 4: e5108, 2009
39. Hansen AR, Barnés CM, Folkman J, McElrath TF: Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr 156: 532-536, 2010
40. Tang JR, Karumanchi SA, Seedorf G, Markham N, Abman SH: Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 302: L36-L46, 2012
41. Wang A, Holston AM, Yu KF, Zhang J, Toporsian M, Karumanchi SA, Levine RJ: Circulating anti-angiogenic factors during hypertensive pregnancy and increased risk of respiratory distress syndrome in preterm neonates. J Matern Fetal Neonatal Med 25: 1447-1452, 2012
42. Feng F, Cheng Y, Liu QH: Bevacizumab treatment reduces retinal neovascularization in amouse model of retinopathy of prematurity. Int J Ophthalmol 7: 608-613, 2014
43. Yenice O, Cerman E, Ashour A, Firat R, Haklar G, Sirikci O, Akman I, Kazokoglu H: Serum erythropoietin, insulin-like growth factor 1, and vascular endothelial growth factor in etiopathogenesis of retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina 44: 549-554, 2013
44. Gordon BR, Kelsey SF, BilheimerDW, Brown DC, Dau PC, Gotto AM Jr, Illingworth DR, Jones PH, Leitman SF, Prihoda JS, et al. ; The Liposorber Study Group: Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol 70: 1010-1016, 1992